Use of inhaled corticosteroid; a risk for reduced bone density? A population based study. The bronchial obstruction study in Nord-Trøndelag (BONT)

A. Langhammer, E. Norjavaara, M. G. de Verdier, R. Johnsen, L. Bjermer (Verdal, Trondheim, Norway; Göteborg, Lund, Sweden)

Source: Annual Congress 2001 - Asthma and interstitial lung disease
Session: Asthma and interstitial lung disease
Session type: Thematic Poster Session
Number: 2962
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Langhammer, E. Norjavaara, M. G. de Verdier, R. Johnsen, L. Bjermer (Verdal, Trondheim, Norway; Göteborg, Lund, Sweden). Use of inhaled corticosteroid; a risk for reduced bone density? A population based study. The bronchial obstruction study in Nord-Trøndelag (BONT). Eur Respir J 2001; 16: Suppl. 31, 2962

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Inhaled corticosteroids (ICS) and bone mineral density (BMD) - a follow-up study. The bronchial obstruction in Nord-Trøndelag study (BONT)
Source: Eur Respir J 2004; 24: Suppl. 48, 601s
Year: 2004

A study of exhaled NO (FENO) measurement used to determine asthma control, dose of inhaled corticosteroid and cost in a developing country
Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage?
Year: 2015


Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016

Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014


Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021


Absence of nonspecific bronchial responsiveness (NSBR) in occupational asthma (OA): A case-series study
Source: Annual Congress 2012 - Occupational asthma
Year: 2012


Use of inhaled corticosteroids and the risk of osteoporosis: an international cohort study
Source: International Congress 2018 – Epidemiology of asthma, COPD and factors that associate with lung function
Year: 2018

A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013

The prevalence of bronchial asthma symptoms among adult population of Moscow (a population-based study).
Source: International Congress 2018 – Epidemiology of asthma and allergy: prevalence, incidence and risk factors
Year: 2018

Lung function, bronchial hyperresponsiveness (BHR) and metabolic risk factors in adults: Preliminary results from the gene environment interaction in respiratory disease (GEIRD) survey
Source: Annual Congress 2011 - Comorbidities and impact on society of asthma and COPD
Year: 2011

Effect of inhaled steroids on lung function in young children: a cohort study
Source: Eur Respir J 2004; 23: 869-875
Year: 2004



Changes in symptoms, respiratory function, airway inflammation, and airway hyperresponsiveness over 10 year of inhaled corticosteroid therapy in adult asthma patients
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015


QAW039 (fevipiprant) improves lung function and control of asthma symptoms in patients with more severe air flow limitation: A proof-of-concept study
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015


Inhaled antibiotic treatment reduces the frequency of infective exacerbations in bronchiectasis: a single center, real life study
Source: International Congress 2019 – Complex respiratory infections in clinical practice
Year: 2019


Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021


Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis)
Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD
Year: 2018


Budesonid/formoterol easyhaler: clinical efficiency and adherence to treatment in patients with partly controlled bronchial asthma (BA).
Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies
Year: 2017


Safety of bronchial thermoplasty (bt), a novel procedure for severe asthma; positive safety profile in the air2 trial
Source: Annual Congress 2009 - Treatment beyond inhalers
Year: 2009

The concept study: comparative influence of two treatment strategies on airway response to AMP
Source: Annual Congress 2005 - Combination therapy for asthma. Which, why and how?
Year: 2005

Inhaled formulation of angiotensin-(1-7) produces lung protective effects in a model of chronic asthma.
Source: International Congress 2018 – Identification of therapeutic targets for asthma
Year: 2018